×
About 6,166,126 results
Selinexor/Bortezomib/Dexamethasone Triplet Improves PFS, ORR in Multiple Myeloma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200181/full/

May 28th, 2020 - Once-weekly selinexor, bortezomib, and dexamethasone (SVd) for relapsed/refractory multiple myeloma (MM) significantly improved progression-free survival (PFS) and overall response rate (ORR) when compared with twice-weekly bortezomib and dexamethasone (Vd), according to initial results from the phase III BOSTON trial (Abstract 8501).

KarMMa: BCMA-Targeting CAR T Excellent Option for Relapsed/Refractory Myeloma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200194/full/

May 28th, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) resulted in deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to phase II data from the KarMMa trial (Abstract 8503).

Early Data Show Bispecific Antibody Teclistamab Safe, Active in Relapsed/Refractory Multiple Myeloma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200175/full/

May 28th, 2020 - Teclistamab, a IgG-4 bispecific antibody targeting BCMA and CD3, appears to be safe in patients with relapsed or refractory multiple myeloma, according to phase I data presented during the ASCO20 Virtual Scientific Program (Abstract 100).

Donafenib Improves OS in Hepatocellular Carcinoma Compared With Sorafenib
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200179/full/

May 28th, 2020 - Donafenib significantly improved overall survival (OS) rates compared with sorafenib in patients with hepatocellular carcinoma (HCC) and did so with favorable safety and tolerability, according to a new study (Abstract 4506).

ADJUVANT-CTONG 1104 Results Underscore the Value of Using EGFR-Targeted Therapy in EGFR-Mutated NSCLC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200182/full/

May 28th, 2020 - During the 2017 ASCO Annual Meeting, investigators of the ADJUVANT-CTONG 1104 trial first reported that postsurgical treatment with gefitinib conferred a significant 10.7-month improvement in disease-free survival (DFS) compared with standard doublet chemotherapy in patients with stage II-IIIA EGFR-positive non–small cell lung cancer (NSCLC), thus meeting the primary study endpoint (HR 0.60, 95...

Trastuzumab Fails to Improve DFS When Added to Trimodality Therapy for Operable Esophageal Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200178/full/

May 28th, 2020 - Although HER-targeted therapy represents a standard of care for many HER2-positive malignancies, data supporting its benefit for patients with early-stage HER2-overexpressing esophageal adenocarcinoma are lacking. Results of the RTOG 1010 trial demonstrated that adding trastuzumab both before and after chemoradiotherapy and surgery did not significantly improve disease-free survival (DFS) beyon...

Final IDEA Collaboration Results Support Just 3 Months of Adjuvant CAPOX for Most Patients With Stage III Colon Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200177/full/

May 28th, 2020 - Prospective evaluation of nearly 13,000 individuals with stage III colon cancer found minimal difference in 5-year overall survival (OS) with 3 versus 6 months of adjuvant CAPOX or FOLFOX for the majority of patients, according to the final results of the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration (Abstract 4004). In contrast, the shorter treatment course pr...

Dr. Sondos Zayed Receives the Philip Francis Mulvey, III, Endowed Merit Award for Research on Opioid Addiction Risk in Patients With Head and Neck Cancer
https://dailynews.ascopubs.org/do/10.5555/ADN.20.200185/full/

May 28th, 2020 - A new merit award memorializing a remarkable man’s lifetime mission of mentorship is honoring a particularly appropriate inaugural recipient—Sondos Zayed, MD, an early-career resident clinical investigator at Western University, Canada.

Three Years of Imatinib Improves OS in High-Risk Operable GIST
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200183/full/

May 28th, 2020 - Approximately half of deaths can be avoided with the use of 3 years of adjuvant imatinib in the first decade after surgery for high-risk gastrointestinal stromal tumors (GIST), according to long-term data from the Scandinavian Sarcoma Group XVIII/German trial (Abstract 11503).

Triplet Combination Considered New Standard of Care for Patients With HER2-Positive Metastatic Breast Cancer, Brain Metastases
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200164/full/

May 28th, 2020 - Exploratory analyses conducted in a subset of heavily pretreated patients with brain metastases enrolled on the HER2CLIMB trial found that tucatinib in combination with trastuzumab and capecitabine reduces the risk of intracranial (IC) progression and death in patients with HER2-positive metastatic breast cancer (MBC; Abstract 1005). Nancy U. Lin, MD, of Dana-Farber Cancer Institute, presented ...

Upfront Radiation Added to TKI Therapy Improves Outcomes in Oligometastatic NSCLC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200171/full/

May 28th, 2020 - The addition of stereotactic body radiation therapy (SBRT) to tyrosine kinase inhibitor (TKI) therapy yielded longer progression-free survival (PFS) and overall survival (OS) than TKI therapy alone in patients with EGFR-mutant oligometastatic non–small cell lung cancer (NSCLC), according to an interim analysis of an open-label phase III trial presented during the ASCO20 Virtual Scientific Progr...

Palliative Care Improves Quality of Life in Patients With AML
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200172/full/

May 28th, 2020 - When patients with acute myeloid leukemia (AML) undergo intensive chemotherapy treatment, their quality of life (QoL) and mood are negatively affected. Areej El-Jawahri, MD, of Massachusetts General Hospital, presented the results of a multicenter study conducted in patients with AML to determine if integrated palliative and oncology care could improve QoL and other important aspects of patient...

T-DM1 Does Not Improve Safety or Efficacy in HER2-Positive Early Breast Cancer; Favorable iDFS Reported
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200162/full/

May 28th, 2020 - Findings from the primary analysis of the KAITLIN trial suggest that replacement of adjuvant taxane with trastuzumab emtansine (T-DM1) does not improve survival or safety for patients with HER2-positive early-stage breast cancer (Abstract 500). However, both treatments demonstrated outstanding long-term invasive disease–free survival (iDFS) in a high-risk population. Study author Nadia Harbeck,...

18F-DCFPyL–PET/CT Imaging Improves Diagnostic Capability in Relapsed Prostate Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200168/full/

May 28th, 2020 - Imaging with 18F-DCFPyL–PET/CT was found to be diagnostically effective, often guiding a change in treatment plan, in men with biochemically relapsed prostate cancer, according to the results of the phase III CONDOR study presented during the ASCO20 Virtual Scientific Program (Abstract 5501).

Apalutamide, Darolutamide, Enzalutamide Yield OS Benefit in nmCRPC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200161/full/

May 28th, 2020 - Final survival results from three randomized, placebo-controlled trials, along with a safety analysis across all three, are helping to clarify the treatment landscape for nonmetastatic castration-resistant prostate cancer (nmCRPC). The results will be presented during the ASCO20 Virtual Scientific Program.

Strategies Emerge for Chemotherapy De-escalation in HER2-Positive Breast Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200163/full/

May 28th, 2020 - Two studies presented during the ASCO20 Virtual Scientific Program show the potential to de-escalate chemotherapy in the setting of dual HER2 blockade for patients with HER2-positive breast cancer.

https://dailynews.ascopubs.org/do/10.1200/ADN.20.200143/full/
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200143/full/

May 19th, 2020 - In the phase III PROfound trial (NCT02987543), men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving enzalutamide or abiraterone and who had homologous recombination repair (HRR) gene alterations demonstrated longer progression-free survival and better measures of response when treated with olaparib than enzalutamide or abiraterone.1 Now, t...

Integrated Tumor and Immune Cell Multiomic Analyses Predict ICB Response in Advanced Melanoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200165/full/

May 28th, 2020 - Immunoglobulin (Ig) gene rearrangements, expressed tumor mutation burden (TMB), tumor aneuploidy, and pre-existing T- and B-cell immunity may predict response to immune checkpoint blockade (ICB) and subsequent prognosis in patients with advanced melanoma, according to a study (Abstract 10009) presented by Valsamo Anagnostou, MD, PhD, of the Bloomberg-Kimmel Institute for Cancer Immunotherapy at...

Dr. Alice Yu, Pioneer in Immunotherapy for Neuroblastoma, to Receive Pediatric Oncology Award
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200152/full/

May 19th, 2020 - Alice Yu, MD, PhD, of the University of California San Diego School of Medicine, will receive the 2020 Pediatric Oncology Award. The award, first presented in 2002, recognizes a pediatric oncologist who has demonstrated outstanding leadership or achievement in the field.

Interim Analysis of GAIN-2 Indicates Dose-Dense Chemotherapy Regimens Are Equivalent
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200142/full/

May 28th, 2020 - An interim analysis of the GAIN-2 study in patients with high-risk early-stage breast cancer indicated that the use of neoadjuvant/adjuvant intense, dose-dense epirubicin, nab-paclitaxel, and cyclophosphamide (iddEnPC) and dose-dense, dose-tailored epirubicin/cyclophosphamide followed by dose-dense, dose-tailored docetaxel (dtEC-dtD) were equivalent (Abstract 516).